[go: up one dir, main page]

NO20054017L - 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem - Google Patents

2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem

Info

Publication number
NO20054017L
NO20054017L NO20054017A NO20054017A NO20054017L NO 20054017 L NO20054017 L NO 20054017L NO 20054017 A NO20054017 A NO 20054017A NO 20054017 A NO20054017 A NO 20054017A NO 20054017 L NO20054017 L NO 20054017L
Authority
NO
Norway
Prior art keywords
derivatives
acetic acids
aryl acetic
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO20054017A
Other languages
English (en)
Other versions
NO334149B1 (no
Inventor
Riccardo Bertini
Cinzia Bizzarri
Marcello Allegretti
Maria Candida Cesta
Francesco Colotta
Alessio Moriconi
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of NO20054017L publication Critical patent/NO20054017L/no
Publication of NO334149B1 publication Critical patent/NO334149B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Det er beskrevet utvalgte 2-aryleddiksyrer, deres derivater og farmasøytiske sammensetninger som inneholder disse forbindelsene som er nyttige til å inhibere kjemotaktisk aktivering av nøytrofiler (PMN-leukocytter) indusert ved interaksjon av interleukin-8 (IL-8) med CXCR1- og CXCR2-membranreseptorer. Forbindelsene til forhindring og behandling av patologier avledet fra nevnte aktivering. Særlig mangler 2(orto)-substituerte aryleddiksyrer og deres derivater, så som amider og sulfonamider, syklo-oksygenaseinhibisjonsaktivitet og er spesielt nyttig til behandling av nøytrofilavhengige patologier så som psoriasis, ulcererende kolitt, melanom, kronisk obstruktiv lungesykdom (COPD), bulløs pemfigoid, reumatoid artritt, idiopatisk fibrose, glomerulonefritt og til forhindring og behandling av skade forårsaket av ischemi og reperfusjon.
NO20054017A 2003-02-06 2005-08-30 2-aryl-eddiksyrer, deres derivater og farmasøytisk sammensetninger som inneholder dem NO334149B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002716 2003-02-06
PCT/EP2004/001021 WO2004069782A2 (en) 2003-02-06 2004-02-04 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20054017L true NO20054017L (no) 2005-08-30
NO334149B1 NO334149B1 (no) 2013-12-16

Family

ID=32842696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054017A NO334149B1 (no) 2003-02-06 2005-08-30 2-aryl-eddiksyrer, deres derivater og farmasøytisk sammensetninger som inneholder dem

Country Status (14)

Country Link
US (3) US7776909B2 (no)
EP (1) EP1590314B1 (no)
JP (1) JP5208411B2 (no)
CN (1) CN100562511C (no)
AU (2) AU2004210082B2 (no)
CA (1) CA2511582C (no)
DK (1) DK1590314T3 (no)
ES (1) ES2551929T3 (no)
HU (1) HUE026285T2 (no)
NO (1) NO334149B1 (no)
PT (1) PT1590314E (no)
RU (1) RU2356887C2 (no)
SI (1) SI1590314T1 (no)
WO (1) WO2004069782A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
PL1776336T3 (pl) * 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN103159674A (zh) * 2013-04-03 2013-06-19 苏州安诺生物医药技术有限公司 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途
CN107398233B (zh) * 2016-05-20 2019-07-05 中国石油天然气股份有限公司 一种酰胺基苯磺酸盐表面活性剂及其制备方法和应用
CA3112073A1 (en) * 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB119562A (en) * 1917-10-22 1918-10-10 William Davidson Improvements in Implements for Cultivating or Pulverising the Soil.
US2425821A (en) * 1944-04-19 1947-08-19 Paul A Peters Method and apparatus for determining the eye color reflex sensation
US2425721A (en) * 1945-08-06 1947-08-19 Univ Michigan Thiophene compounds and methods of obtaining the same
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
FR8113M (no) * 1967-07-26 1970-08-03
ES356485A1 (es) * 1967-07-26 1970-01-16 Mcneilab Inc Un procedimiento para la preparacion de nuevos acidos 5- aroilpirrol-2-carboxilicos y derivados de acido carboxilico.
US3752826A (en) * 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US3833608A (en) * 1970-11-23 1974-09-03 Merck Sharp & Dohme Indole-3-methanesulfonamides
US3883541A (en) * 1971-02-22 1975-05-13 Dow Chemical Co 4-Amino-3,5,6-trichloro-2-(functionally substituted methyl) pyridine compounds
WO2000010610A2 (en) * 1998-08-19 2000-03-02 Theramark Limited Drug targeting
CN1384832A (zh) 1999-11-18 2002-12-11 诺瓦提斯公司 作为农药的氨基杂环基酰胺化合物
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
WO2003022814A1 (en) * 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds

Also Published As

Publication number Publication date
HK1090356A1 (zh) 2006-12-22
WO2004069782A2 (en) 2004-08-19
RU2356887C2 (ru) 2009-05-27
WO2004069782A3 (en) 2004-09-16
AU2004210082B2 (en) 2011-03-17
CN100562511C (zh) 2009-11-25
US7776909B2 (en) 2010-08-17
US20110195967A1 (en) 2011-08-11
HUE026285T2 (en) 2016-05-30
DK1590314T3 (en) 2015-11-02
US20060223842A1 (en) 2006-10-05
NO334149B1 (no) 2013-12-16
ES2551929T3 (es) 2015-11-24
AU2011201305B2 (en) 2013-01-31
CN1768026A (zh) 2006-05-03
US20100267726A1 (en) 2010-10-21
US8871784B2 (en) 2014-10-28
EP1590314B1 (en) 2015-08-05
CA2511582A1 (en) 2004-08-19
AU2011201305A1 (en) 2011-04-07
CA2511582C (en) 2012-01-24
AU2004210082A1 (en) 2004-08-19
US8648110B2 (en) 2014-02-11
JP2006516592A (ja) 2006-07-06
SI1590314T1 (sl) 2015-12-31
RU2005127777A (ru) 2006-05-27
PT1590314E (pt) 2015-11-19
JP5208411B2 (ja) 2013-06-12
EP1590314A2 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
CY1109687T1 (el) Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν
DK1606248T3 (da) Sulfonsyrer, deres derivater og farmaceutiske sammensætninger indeholdende dem
NO20054017L (no) 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem
Berkhout et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach
Folkes et al. Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1
Wityak et al. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck
BRPI0515524A (pt) compostos quìmicos
ATE432259T1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
CY1118109T1 (el) (r)-apyλaλkyλamino παραγωγα και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτα
Gilbert et al. N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2)
Shah et al. A review on ROCK-II inhibitors: from molecular modelling to synthesis
Porter et al. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists
Finke et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl) amino]-2-(phenyl)-4-[4-(substituted) piperidin-1-yl] butanes
BR0214322A (pt) ácidos 2-aril-propiÈnicos e composições farmacêuticas contendo os mesmos
Yin et al. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors
DK1856031T3 (da) 2-arylpropionsyrederivater og farmaceutiske sammensætninger indeholdende disse
Ikegashira et al. Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models
WO2005105092A3 (en) 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
Skotnicki et al. TNF-α converting enzyme (TACE) as a therapeutic target
Parlow et al. Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex
Miller et al. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen
DE602006007210D1 (de) Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
WO2005120505A3 (en) Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity
Sutton et al. From virtual to clinical: the discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor
Crosignani et al. Discovery of a novel series of CXCR3 antagonists

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: DOMPE FARMACEUTICI S.P.A., IT

MM1K Lapsed by not paying the annual fees